Amgen Inc. with ticker code (AMGN) now have 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $380.00 and $170.00 suggesting an average analyst share price target price of $318.72. (at the time of writing). Given that the stocks previous close was at $321.67 this would indicate that there is a downside of -.9%. It’s also worth noting that there is a 50 day moving average of $306.96 and the 200 day MA is $286.92. The company has a market cap of 174.39B. The stock price for the company is currently $325.09 USD
The potential market cap would be $172,790,349,334 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 46.51, revenue per share of $55.15 and a 4.88% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
